Objective : The Pten/AKT/mTOR pathway is one of the most critical pathways in tumor proliferation. The present research aimed to analyze the interaction between Pten gene and AKT/mTOR pathway in endometrial cancer cell lines. Methods : TCGA analysis was used to study the relationship between Pten expression and survival of endometrial cancer patients. Human endometrial cancer cell lines with low Pten expression (Ishikawa) and with high Pten expression (HEC-1-A) were selected. Plasmid transfection was used to regulate the Pten expression in the cell lines. QRT-PCR and Western Blot were adopted to detect Pten/AKT/mTOR expressions in tumor cells. Western blot of Ki-67 and CCK-8 were adopted to detect the activity of cells proliferation. A p < 0.05 was considered to be statistically significant. Results : The TCGA analysis showed the Pten expression was associated with survival of endometrial cancer patients significantly. Plasmid transfections elevated Pten expression in Ishikawa and decreased Pten expression in HEC-1-A cells. After the plasmid transfection, with overexpression of Pten in Ishikawa cell line, the Western Blot and QRT-PCR revealed the AKT/mTOR pathway is restrained, leading to decreased cell proliferation; with Pten decreased in HEC-1-A cells, the AKT/mTOR pathway is activated, leading to increased cell proliferation. Conclusions : A decreased expression of Pten gene in Ishikawa and HEC-1-A cell lines could activate AKT/mTOR pathway and promote tumor cells proliferation.
{"title":"Interaction of Pten gene and AKT/mTOR pathway in endometrial adenocarcinoma proliferation","authors":"D. Tang, M. Xi, Xi Zeng","doi":"10.31083/j.ejgo4302033","DOIUrl":"https://doi.org/10.31083/j.ejgo4302033","url":null,"abstract":"Objective : The Pten/AKT/mTOR pathway is one of the most critical pathways in tumor proliferation. The present research aimed to analyze the interaction between Pten gene and AKT/mTOR pathway in endometrial cancer cell lines. Methods : TCGA analysis was used to study the relationship between Pten expression and survival of endometrial cancer patients. Human endometrial cancer cell lines with low Pten expression (Ishikawa) and with high Pten expression (HEC-1-A) were selected. Plasmid transfection was used to regulate the Pten expression in the cell lines. QRT-PCR and Western Blot were adopted to detect Pten/AKT/mTOR expressions in tumor cells. Western blot of Ki-67 and CCK-8 were adopted to detect the activity of cells proliferation. A p < 0.05 was considered to be statistically significant. Results : The TCGA analysis showed the Pten expression was associated with survival of endometrial cancer patients significantly. Plasmid transfections elevated Pten expression in Ishikawa and decreased Pten expression in HEC-1-A cells. After the plasmid transfection, with overexpression of Pten in Ishikawa cell line, the Western Blot and QRT-PCR revealed the AKT/mTOR pathway is restrained, leading to decreased cell proliferation; with Pten decreased in HEC-1-A cells, the AKT/mTOR pathway is activated, leading to increased cell proliferation. Conclusions : A decreased expression of Pten gene in Ishikawa and HEC-1-A cell lines could activate AKT/mTOR pathway and promote tumor cells proliferation.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49547882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ala Aiob, Karina Naškoviča, Inna Amdur Zilberfarb, A. Sharon, J. Bornstein, L. Lowenstein
Objective : Molar pregnancy is the most common type of gestational trophoblastic disease. Gestational trophoblastic disease is characterized by lower absolute and relative lymphocyte levels and a lower white blood cell (WBC) count relative to normal pregnancy. However, no studies have examined the WBC count relative to missed abortion. The aim of this study was to investigate whether blood parameters, such as neutrophil and lymphocyte counts, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), WBC count and platelets can distinguish gestational trophoblastic disease from missed abortion. Methods : This retrospective study included 104 women diagnosed with molar pregnancy and 110 women with missed abortions during 2010–2020 at one institution. Sixty-nine women had partial moles (PM) and 35 had complete moles (CM). We extracted and compared maternal and pregnancy characteristics, and laboratory parameters of all the women with molar pregnancy, and separately for those with PM and CM, compared to women with missed abortion. Results : The mean neutrophil level was higher in the molar pregnancy than the missed abortion group (5.67 ± 1.92 vs. 5.02 ± 1.65, p = 0.013); the patients with PM largely drove this difference. In multivariable linear models, women with molar pregnancy were more likely to have higher neutrophil values than women with missed abortion ( p = 0.023). Platelet, WBC, NLR and PLR values did not differ significantly between women with gestational trophoblastic disease and women with missed abortion. Conclusions : A higher neutrophil level was observed among women with molar pregnancies than among women with missed abortion. This suggests that molar pregnancies may cause a higher inflammatory response due to continued trophoblastic growth. However, the magnitude of the difference was small and not useful for establishing a diagnosis.
{"title":"Complete blood count parameters, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in hydatidiform mole versus missed abortion","authors":"Ala Aiob, Karina Naškoviča, Inna Amdur Zilberfarb, A. Sharon, J. Bornstein, L. Lowenstein","doi":"10.31083/j.ejgo4302023","DOIUrl":"https://doi.org/10.31083/j.ejgo4302023","url":null,"abstract":"Objective : Molar pregnancy is the most common type of gestational trophoblastic disease. Gestational trophoblastic disease is characterized by lower absolute and relative lymphocyte levels and a lower white blood cell (WBC) count relative to normal pregnancy. However, no studies have examined the WBC count relative to missed abortion. The aim of this study was to investigate whether blood parameters, such as neutrophil and lymphocyte counts, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), WBC count and platelets can distinguish gestational trophoblastic disease from missed abortion. Methods : This retrospective study included 104 women diagnosed with molar pregnancy and 110 women with missed abortions during 2010–2020 at one institution. Sixty-nine women had partial moles (PM) and 35 had complete moles (CM). We extracted and compared maternal and pregnancy characteristics, and laboratory parameters of all the women with molar pregnancy, and separately for those with PM and CM, compared to women with missed abortion. Results : The mean neutrophil level was higher in the molar pregnancy than the missed abortion group (5.67 ± 1.92 vs. 5.02 ± 1.65, p = 0.013); the patients with PM largely drove this difference. In multivariable linear models, women with molar pregnancy were more likely to have higher neutrophil values than women with missed abortion ( p = 0.023). Platelet, WBC, NLR and PLR values did not differ significantly between women with gestational trophoblastic disease and women with missed abortion. Conclusions : A higher neutrophil level was observed among women with molar pregnancies than among women with missed abortion. This suggests that molar pregnancies may cause a higher inflammatory response due to continued trophoblastic growth. However, the magnitude of the difference was small and not useful for establishing a diagnosis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47371475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Krämer, C. Rogmans, Dilek Saylan, D. Friedrich, C. Kraft, G. Rogmans, M. Wirtz, M. Friedrich
Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 ( BRCA1 )-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.
{"title":"Treatment Progress in Triple Negative Breast Cancer","authors":"S. Krämer, C. Rogmans, Dilek Saylan, D. Friedrich, C. Kraft, G. Rogmans, M. Wirtz, M. Friedrich","doi":"10.31083/j.ejgo4302040","DOIUrl":"https://doi.org/10.31083/j.ejgo4302040","url":null,"abstract":"Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 ( BRCA1 )-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47437676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-22DOI: 10.21203/rs.3.rs-1374888/v1
Qiuyang Jing, Ying He
Background: Serous carcinoma arising in adenomyosis is rare, only 8 cases have been reported in the literature. Primary small cell carcinoma of ovary - pulmonary type (SCOOPT) is a rare, aggressive entity associated with poor outcomes and limited treatment options. The two malignant tumors synchronously happen at one patient has never been reported before.Case presentation: We summarized and analyzed the clinicopathological features of 1 serous carcinoma arising in adenomyosis synchronous with SCOOPT and reviewed the literature. A 60-year-old postmenopausal woman presented to our hospital with abdominal distension, abdominal pain, and constipation. Colonoscopy and computed tomography (CT) scan of pulmonary showed no abnormalities. Ultrasonography and CT scan revealed a solid-cystic mass in the pelvic cavity, slightly thickened uterine myometrium at the fundus with heterogeneous echo. A total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy were performed. The final pathology showed serous carcinoma originating from adenomyosis, while the eutopic endometrium and both fallopian epithelia were identified with no cancer. The solid-cystic mass in the right ovary is diagnosed with SCCOPT and metastasis to the myometrium of the uterus. The prognosis of previously reported cancers of adenomyosis origin and SCOOPT were both poor, while our case was alive without disease during the 6-month follow-up.Conclusion: We believe this case report will expand our recognition of the coexistence of serous carcinoma arising in adenomyosis with small cell carcinoma of the ovary–pulmonary type (SCOOPT).
{"title":"Synchronous serous carcinoma arising in adenomyosis and small cell carcinoma of ovary - pulmonary type (SCOOPT): a case report and literature review","authors":"Qiuyang Jing, Ying He","doi":"10.21203/rs.3.rs-1374888/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-1374888/v1","url":null,"abstract":"\u0000 Background: Serous carcinoma arising in adenomyosis is rare, only 8 cases have been reported in the literature. Primary small cell carcinoma of ovary - pulmonary type (SCOOPT) is a rare, aggressive entity associated with poor outcomes and limited treatment options. The two malignant tumors synchronously happen at one patient has never been reported before.Case presentation: We summarized and analyzed the clinicopathological features of 1 serous carcinoma arising in adenomyosis synchronous with SCOOPT and reviewed the literature. A 60-year-old postmenopausal woman presented to our hospital with abdominal distension, abdominal pain, and constipation. Colonoscopy and computed tomography (CT) scan of pulmonary showed no abnormalities. Ultrasonography and CT scan revealed a solid-cystic mass in the pelvic cavity, slightly thickened uterine myometrium at the fundus with heterogeneous echo. A total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy were performed. The final pathology showed serous carcinoma originating from adenomyosis, while the eutopic endometrium and both fallopian epithelia were identified with no cancer. The solid-cystic mass in the right ovary is diagnosed with SCCOPT and metastasis to the myometrium of the uterus. The prognosis of previously reported cancers of adenomyosis origin and SCOOPT were both poor, while our case was alive without disease during the 6-month follow-up.Conclusion: We believe this case report will expand our recognition of the coexistence of serous carcinoma arising in adenomyosis with small cell carcinoma of the ovary–pulmonary type (SCOOPT).","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43222197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PARP inhibition in ovarian cancer: what is still missing?","authors":"M. Morotti, E. Ghisoni","doi":"10.31083/j.ejgo4301016","DOIUrl":"https://doi.org/10.31083/j.ejgo4301016","url":null,"abstract":"1Ludwig Institute for Cancer Research, Bâtiment AGORA, 1005 Lausanne, Switzerland 2Department of Gynecology, CHUV-Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland 3Department of Oncology, Immuno-Oncology Service, CHUV-Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland *Correspondence: drmorottimatteo@gmail.com (Matteo Morotti) Academic Editor: Enrique Hernandez Submitted: 11 October 2021 Revised: 16 November 2021 Accepted: 19 November 2021 Published: 15 February 2022","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47473450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Theodoulidis, T. Mikos, D. Tsolakidis, L. Zepiridis, G. Grimbizis
Endometrial cancer (EC) survivors are increasing progressively. However, treating this disorder may detrimentally affect the pelvic organs, resulting in pelvic floor disorders (PFD): urinary incontinence, pelvic organ prolapse, and bowel dysfunction. The aim of this review is to investigate the prevalence of PFD in EC survivors following both surgical and nonsurgical treatments. The authors conducted a structured search in the following databases: MEDLINE, EMBASE, Global Health, The Cochrane Library, and Web of Science from inception until August 2021. The inclusion criteria were: (1) women with EC, (2) observational studies, (3) original data, (4) PFD result evaluation, and (5) the use of verified tools for the evaluation of PFD. The initial search found 590 articles for PFD and endometrial cancer. Only 10 of the studies were finally available for further analysis, including 1849 individuals with EC. In total, the incidence of UI increased from 7.6% to 20.8% after EC therapy. The incidence of stress and urge UI after treatment ranged from 23 to 74.3% and 20.8 to 71.4%, respectively. The prevalence of POP was as high as 13.6% in 638 EC survivors. The prevalence of fecal incontinence was 21% in 732 EC survivors. In conclusion, PFDs are common after endometrial cancer treatment. The lack of comparative studies between the type of EC and the type of treatment limits further exploration of the differences in PFD frequency among EC survivors and the variety of EC treatments.
子宫内膜癌(EC)幸存者正在逐渐增加。然而，治疗这种疾病可能会对盆腔器官产生不利影响，导致盆底疾病(PFD):尿失禁、盆腔器官脱垂和肠功能障碍。本综述的目的是调查手术和非手术治疗后EC幸存者中PFD的患病率。作者对以下数据库进行了结构化检索:MEDLINE、EMBASE、Global Health、Cochrane Library和Web of Science，检索时间从成立到2021年8月。纳入标准为:(1)患有EC的女性，(2)观察性研究，(3)原始数据，(4)PFD结果评估，(5)使用经过验证的PFD评估工具。最初的搜索发现了590篇关于PFD和子宫内膜癌的文章。最终只有10项研究可供进一步分析，其中包括1849名EC患者。总的来说，EC治疗后尿失禁的发生率从7.6%增加到20.8%。治疗后应激性尿失禁发生率为23% ~ 74.3%，急迫性尿失禁发生率为20.8% ~ 71.4%。638例EC幸存者中POP患病率高达13.6%。732例EC幸存者中大便失禁的发生率为21%。总之，子宫内膜癌治疗后常见PFDs。缺乏EC类型和治疗类型之间的比较研究，限制了进一步探索EC幸存者之间PFD频率的差异和EC治疗的多样性。
{"title":"Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review","authors":"I. Theodoulidis, T. Mikos, D. Tsolakidis, L. Zepiridis, G. Grimbizis","doi":"10.31083/j.ejgo4301020","DOIUrl":"https://doi.org/10.31083/j.ejgo4301020","url":null,"abstract":"Endometrial cancer (EC) survivors are increasing progressively. However, treating this disorder may detrimentally affect the pelvic organs, resulting in pelvic floor disorders (PFD): urinary incontinence, pelvic organ prolapse, and bowel dysfunction. The aim of this review is to investigate the prevalence of PFD in EC survivors following both surgical and nonsurgical treatments. The authors conducted a structured search in the following databases: MEDLINE, EMBASE, Global Health, The Cochrane Library, and Web of Science from inception until August 2021. The inclusion criteria were: (1) women with EC, (2) observational studies, (3) original data, (4) PFD result evaluation, and (5) the use of verified tools for the evaluation of PFD. The initial search found 590 articles for PFD and endometrial cancer. Only 10 of the studies were finally available for further analysis, including 1849 individuals with EC. In total, the incidence of UI increased from 7.6% to 20.8% after EC therapy. The incidence of stress and urge UI after treatment ranged from 23 to 74.3% and 20.8 to 71.4%, respectively. The prevalence of POP was as high as 13.6% in 638 EC survivors. The prevalence of fecal incontinence was 21% in 732 EC survivors. In conclusion, PFDs are common after endometrial cancer treatment. The lack of comparative studies between the type of EC and the type of treatment limits further exploration of the differences in PFD frequency among EC survivors and the variety of EC treatments.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43610486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni
Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.
{"title":"Adjuvant treatment in endometrial cancer: when and what to choose","authors":"M. Paderno, T. Grassi, M. Adorni, Benedetta Zambetti, G. Di Martino, L. Bazzurini, F. Landoni, A. Lissoni","doi":"10.31083/j.ejgo4301018","DOIUrl":"https://doi.org/10.31083/j.ejgo4301018","url":null,"abstract":"Endometrial cancer is the most common gynecological malignancy in developed countries. The management is primarily surgical, but adjuvant treatment may be indicated after surgery, according to the risk of recurrence. This review will focus on the prognostic risk groups presented in the 2020 ESGO/ESTRO/ESP guidelines and the ongoing trials based on new molecular markers that will help to get a more personalized cancer medicine.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43056334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Forte, F. Ferrari, G. Valenti, V. Capozzi, B. Navarro Santana, G. Babin, F. Guyon
Objective: To analyze the surgical treatment of liver metastases from advanced ovarian cancer (AOC) during either primary or interval debulking surgery (PDS or IDS). Data sources, methods of study selection: A systematic research of the literature was conducted in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including observational prospective, retrospective studies, case series and case reports. Tabulation, integration and results: We collected data regarding study features, characteristics of the patients and of liver metastasis, the type of surgical treatment and postoperative morbidity. The type of liver surgery was described according to the terminology of Brisbane 2000 (TB2000). Ten articles were selected, and 61 patients were included, even though data was not complete for all of them. The weighted average age was 57 years old, and most women underwent PDS (n = 21/32 [66%]). The number of liver metastases was available only for 17 patients including 3 (18%) and 14 (82%) with multiple and single lesions, respectively. Metastasis from peritoneal seeding (peritoneal metastasis) was the most common type of lesion (n = 27/42 [64%]). Only in one study the authors declared the specialty of the surgeon performing the procedures (hepatobiliary). Two studies (n = 15) adopted the TB2000 and reported as follow: 47% wedge resections, 33% segmentectomies, 13% hemi-hepatectomies and 7% right-trisegmentectomy. ClavienDindo grade III or greater complications was 13% (n = 2/15). Conclusions: Liver resection is feasible during either PDS or IDS. Single lesion and peritoneal metastasis represent the most common conditions. Wedge liver resection is the most frequent procedure. Prognostic advantage is suggested after liver surgery especially for peritoneal metastasis.
{"title":"Liver surgery for advanced ovarian cancer: a systematic review of literature","authors":"S. Forte, F. Ferrari, G. Valenti, V. Capozzi, B. Navarro Santana, G. Babin, F. Guyon","doi":"10.31083/j.ejgo4301015","DOIUrl":"https://doi.org/10.31083/j.ejgo4301015","url":null,"abstract":"Objective: To analyze the surgical treatment of liver metastases from advanced ovarian cancer (AOC) during either primary or interval debulking surgery (PDS or IDS). Data sources, methods of study selection: A systematic research of the literature was conducted in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including observational prospective, retrospective studies, case series and case reports. Tabulation, integration and results: We collected data regarding study features, characteristics of the patients and of liver metastasis, the type of surgical treatment and postoperative morbidity. The type of liver surgery was described according to the terminology of Brisbane 2000 (TB2000). Ten articles were selected, and 61 patients were included, even though data was not complete for all of them. The weighted average age was 57 years old, and most women underwent PDS (n = 21/32 [66%]). The number of liver metastases was available only for 17 patients including 3 (18%) and 14 (82%) with multiple and single lesions, respectively. Metastasis from peritoneal seeding (peritoneal metastasis) was the most common type of lesion (n = 27/42 [64%]). Only in one study the authors declared the specialty of the surgeon performing the procedures (hepatobiliary). Two studies (n = 15) adopted the TB2000 and reported as follow: 47% wedge resections, 33% segmentectomies, 13% hemi-hepatectomies and 7% right-trisegmentectomy. ClavienDindo grade III or greater complications was 13% (n = 2/15). Conclusions: Liver resection is feasible during either PDS or IDS. Single lesion and peritoneal metastasis represent the most common conditions. Wedge liver resection is the most frequent procedure. Prognostic advantage is suggested after liver surgery especially for peritoneal metastasis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46694859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soichiro Suzuki, Y. Ota, Rikiya Sano, Yumiko Morimoto, T. Moriya, M. Shiota
Growing teratoma syndrome (GTS) is a condition characterized by tumor growth during or after chemotherapy for a germ cell tumor, albeit with normal tumor marker levels in the absence of histopathological evidence of immature teratoma components. We encountered a 10-cm large GTS lesion in the para-aorti nodes after fertility-preserving surgery for a grade 3 ovarian immature teratoma. The patient was a 20 year old woman who presented to the hospital with complaints of abdominal pain and swelling. Imaging examination revealed an ovarian tumor mass measuring 24 cm in the abdominal cavity, suspected to be composed of a mixture of fat and other components. The α-fetoprotein (AFP) levels were elevated at 853 ng/mL. We elected to perform fertility-preserving surgery. The surgical findings included a tumor in the right ovary, which was excised without rupture with adnexectomy. The histopathological diagnosis was grade 3 immature teratoma. Palpation of the pelvic and para-aortic lymph node areas did not reveal significant lymphadenopathy. Subsequently, a para-aortic node metastasis (major axis: 8 cm) was discovered before chemotherapy (19 days after surgery). We confirmed that there was no swelling before surgery and assumed that the immature teratoma had recurred. Chemotherapy was initiated, and the serum AFP levels normalized after 4 courses of bleomycin, etoposide, and cisplatin (BEP) therapy. However, the para-aortic node metastasis had grown further (major axis: 10 cm). Another open surgery was performed. The nodal mass was completely excised and pathology revealed only mature teratoma. Growing teratoma syndrome should be considered in the setting of a recurrent mass with negative tumor markers.
{"title":"Growing teratoma syndrome after surgery for ovarian immature teratoma","authors":"Soichiro Suzuki, Y. Ota, Rikiya Sano, Yumiko Morimoto, T. Moriya, M. Shiota","doi":"10.31083/j.ejgo4301017","DOIUrl":"https://doi.org/10.31083/j.ejgo4301017","url":null,"abstract":"Growing teratoma syndrome (GTS) is a condition characterized by tumor growth during or after chemotherapy for a germ cell tumor, albeit with normal tumor marker levels in the absence of histopathological evidence of immature teratoma components. We encountered a 10-cm large GTS lesion in the para-aorti nodes after fertility-preserving surgery for a grade 3 ovarian immature teratoma. The patient was a 20 year old woman who presented to the hospital with complaints of abdominal pain and swelling. Imaging examination revealed an ovarian tumor mass measuring 24 cm in the abdominal cavity, suspected to be composed of a mixture of fat and other components. The α-fetoprotein (AFP) levels were elevated at 853 ng/mL. We elected to perform fertility-preserving surgery. The surgical findings included a tumor in the right ovary, which was excised without rupture with adnexectomy. The histopathological diagnosis was grade 3 immature teratoma. Palpation of the pelvic and para-aortic lymph node areas did not reveal significant lymphadenopathy. Subsequently, a para-aortic node metastasis (major axis: 8 cm) was discovered before chemotherapy (19 days after surgery). We confirmed that there was no swelling before surgery and assumed that the immature teratoma had recurred. Chemotherapy was initiated, and the serum AFP levels normalized after 4 courses of bleomycin, etoposide, and cisplatin (BEP) therapy. However, the para-aortic node metastasis had grown further (major axis: 10 cm). Another open surgery was performed. The nodal mass was completely excised and pathology revealed only mature teratoma. Growing teratoma syndrome should be considered in the setting of a recurrent mass with negative tumor markers.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46360711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
1School of Public Health, Dalian Medical University, 116044 Dalian, Liaoning, China 2School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 Beijing, China *Correspondence: xuepeng_pumc@foxmail.com (Peng Xue); qiaoy@cicams.ac.cn (Youlin Qiao) †These authors contributed equally. Academic Editor: Enrique Hernandez Submitted: 19 November 2021 Revised: 12 December 2021 Accepted: 14 December 2021 Published: 15 February 2022
{"title":"Cervical cancer elimination in the era of COVID-19: the potential role of Artificial Intelligence (AI)-guided digital colposcope cloud platform","authors":"M. J. Mendez, P. Xue, Youlin Qiao","doi":"10.31083/j.ejgo4301019","DOIUrl":"https://doi.org/10.31083/j.ejgo4301019","url":null,"abstract":"1School of Public Health, Dalian Medical University, 116044 Dalian, Liaoning, China 2School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 Beijing, China *Correspondence: xuepeng_pumc@foxmail.com (Peng Xue); qiaoy@cicams.ac.cn (Youlin Qiao) †These authors contributed equally. Academic Editor: Enrique Hernandez Submitted: 19 November 2021 Revised: 12 December 2021 Accepted: 14 December 2021 Published: 15 February 2022","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43390075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：